Articles tagged with Breast Cancer Cells
Researchers found that compounds disrupting EGFR signalling reduced TNBC cell growth by up to 91%. Inhibiting ADAMs may be a promising therapeutic option for TNBC and other cancers with EGFR activity.
Researchers analyzed data from the Cancer Prevention Study II Nutrition Cohort and found that long-term statin use was not associated with overall cancer incidence or increased risk of common types of cancer. Instead, it was linked to lower risks of melanoma, endometrial cancer, and non-Hodgkin lymphoma.
Researchers at the University of Cambridge have discovered that a type of stromal cell found in many cancers expresses fibroblast activation protein alpha, which suppresses the immune response. Destroying these cells allows the immune system to control tumours, paving the way for improved immunological therapies.
Cancer Discovery is a new peer-reviewed journal from the American Association for Cancer Research (AACR), featuring game-changing research and review articles. The journal combines expertise from founding Editors-in-Chief Lewis C. Cantley and José Baselga, with executive editor Mark W. Landis.
Researchers at Mayo Clinic discovered that epithelial cadherin (E-cadherin), a protein believed to be a beneficial tumor suppressor, can act as an oncogene in some lethal brain tumors. This finding suggests E-cadherin expression may promote tumor growth and migration, challenging current understanding of its role in cancer progression.
A research team at Brown University has discovered a key chemical process involved in the development of cancer, particularly breast cancer. The study found that prolactin receptors can come together to form a structure that picks up growth factors leading to cancerous growth.
Researchers found new mechanisms of protease activation, which helps spread cancer. The loss of protease inhibitors antiplasmin and antithrombin occur more in blood from cancer patients compared to healthy persons' blood.
Rensselaer researcher Lee Ligon has won a $720,000 Research Scholar Grant from the American Cancer Society to investigate interactions between breast cancer cells and their surroundings. Her research focuses on how cancerous and non-cancerous cells communicate with each other, potentially shedding light on new treatments.
Researchers have found a synthetic molecule, LLL12, that blocks activation of the oncogene STAT3 in liver cancer cells, halting their survival and increasing sensitivity to chemotherapy. This discovery offers potential for an anti-cancer therapy option.
Seth Field, a UC San Diego researcher, has been awarded $3.86 million to study GOLPH3's role in breast cancer. His project aims to understand the mechanism by which GOLPH3 contributes to cancer and develop new therapy targets.
Researchers developed a novel, dual-platform technology to capture circulating tumor cells (CTCs) in breast cancer more efficiently than traditional methods. The On-Q-ity C5 chip captured 65% of human breast cancer cells compared to 45% with size-based and 16% with antibody affinity methods.
A new disposable device based on microfluidics can efficiently capture cancer cells overexpressing HER2, enabling therapy with trastuzumab. The device offers a non-invasive alternative to current methodologies and has shown promising results in early studies.
Researchers have identified LIMK as a crucial regulator of actin cytoskeleton dynamics in cancer metastasis. Inhibiting LIMK function blocks collective invasion of tumor cells, preventing metastasis in breast and squamous carcinoma cells.
Researchers suggest that stress-induced proteins can help cancer cells survive chemotherapy and radiation treatments. The study found that a protein called heat shock factor-1 activates another protein, Hsp27, which allows cancer cells to survive despite DNA damage.
Researchers found that fat-derived stem cells are safe to use in breast tissue reconstruction after mastectomy as long as there is no evidence of active cancer. The study suggests that dormant cancer cells are not sensitive to the growth signals sent by the stem cells.
Walter and Eliza Hall Institute researcher Dr Marie-Liesse Asselin-Labat is unraveling the mysteries of breast stem cells, their development, and influence by oestrogen and steroids. Her groundbreaking studies aim to uncover how breast cancer progresses and why it sometimes returns.
Researchers found that human breast cancer cells overexpress the alpha 9 subunit of the nAchR, promoting tumor growth. Reducing α9-nAchRs inhibited tumor growth in laboratory experiments.
Researchers at Tel Aviv University have developed a nano-sized vehicle that can deliver chemotherapy drugs directly into cancer cells while avoiding interaction with healthy cells. This technology has the potential to increase the efficiency of chemotherapeutic treatments while reducing their debilitating side effects.
Assistant Professor Annelise Nguyen receives $370,000 grant to study cell communication in cancer cells, potentially leading to enhanced drug treatments. Her work also has potential applications for colon and prostate cancers.
A Kansas State University research team is investigating the mutated ADAM12 gene's role in breast cancer, with findings suggesting its high expression in cancer stem cells. This discovery could lead to more targeted therapies, as conventional treatments often fail on these aggressive cells.
Researchers at Wake Forest University Baptist Medical Center found that low ferroportin levels are associated with aggressive and recurring breast cancers. Testing ferroportin levels may help predict cancer return and guide therapy for patients.
Researchers identified basal cells from benign prostate tissue as a new cell-of-origin for human prostate cancer. This discovery could lead to better predictive and diagnostic tools, as well as the development of targeted treatments. The study provides a novel model system for understanding prostate cancer development and progression.
Researchers at Ohio State University found that breast cancer cells can regulate 14 genes simultaneously in response to estrogen-like compounds like BPA. This mechanism may contribute to cancer development and could serve as a marker for studying environmental exposure.
The study found that Musashi levels increased dramatically as the disease became more aggressive, suggesting it may be a target for future therapies. The researchers also discovered that blocking Musashi could inhibit blast-crisis CML by forcing immature cells to mature and differentiate.
Researchers have successfully induced epigenetic reprogramming in human and mouse breast cancer cells, making them more susceptible to tamoxifen treatment. This targeted epigenetic therapy has shown promising results in reversing the growth and invasive properties of triple-negative breast cancer cells.
Researchers developed a technique to isolate specific cancer proteins using a synthetic nanopolymer. The polymer-based metal-ion affinity capture (PolyMAC) method isolated phosphorylated proteins, which are highly associated with cancer, from a sea of other proteins. This breakthrough may aid in the development of new cancer drugs.
Researchers at Ohio State University discovered how dietary supplement indole-3-carbinol (I3C) blocks cancer cell growth by destroying the Cdc25A molecule. I3C reduced tumor size by up to 65% in breast cancer models, offering potential health benefits and a new strategy for cancer treatment.
A new synthetic molecule targeting non-nuclear estrogen receptors may activate cardiovascular benefits of estrogen without increasing cancer risk. The study suggests this approach could be beneficial for women, particularly those with high cholesterol and diseased arteries.
Researchers have discovered that peach and plum extracts induce the death of breast cancer cells without harming normal cells. The compounds chlorogenic and neochlorogenic were found to be responsible for this differential effect.
Researchers at the University of Pittsburgh Cancer Institute have discovered that inhibiting a key molecule in a DNA repair pathway could make cancer cells more sensitive to radiation therapy while protecting healthy cells. This approach could provide a new means to target and treat cancer more effectively.
A new study reveals that radiation can change the microenvironment of breast cells, allowing abnormal cells to grow and become cancerous. The research found that low-to-moderate doses of radiation promote premature senescence in normal cells, creating space for pre-cancerous cells to grow.
Researchers presented studies on predicting pregnancy-associated breast cancer, post-traumatic stress disorder in breast cancer patients, and novel drug candidates such as flavaglines. The conference also explored the use of circulating tumor cells and gene differences to predict survival outcomes in breast cancer patients.
Researchers have developed a powerful new technique for analyzing genome data from single tumor cells. The breakthrough allows scientists to study the biology of tumor development and identify dangerous cells in small samples. By profiling individual cells, researchers can understand genetic changes that occur as cancer progresses.
Researchers at PMH discovered that progesterone alters breast stem cells, a finding with significant implications for breast cancer risk. The study shows how hormones affect breast stem cells during the reproductive cycle, providing a new pathway to understanding cell growth leading to breast cancer.
Researchers at the University of Kentucky Markey Cancer Center have discovered a key molecular mechanism behind breast tumor cell spread. The finding focuses on Snail's interaction with LSD1 enzyme, which regulates DNA structure and shuts down E-cadherin gene expression, leading to metastasis.
Dr. William Muller's research reveals how a particular gene regulates epithelial cells, leading to the loss of polarity and contributing to breast tumor formation. Reintroducing the gene into tumors shows promise in restoring polarity, suggesting new avenues for cancer treatment.
Researchers discovered that activated farnesoid X receptor (FXR) slows the growth of tamoxifen-resistant breast cancer cells. FXR inhibition reduced survivability in both sensitive and resistant cell types, with more significant effects on the resistant MCF-7TR cells.
Women with preeclampsia have reduced incidence of breast cancer, possibly due to soluble endoglin inhibiting cell growth. However, pups born from mothers with preeclampsia are more likely to develop breast tumors.
Molecular biologist Alan Ashworth will receive a $50,000 grant from the Samuel Waxman Cancer Research Foundation to study PARP inhibitors in BRCA-mutated cancers. His research aims to develop novel treatments for triple-negative breast cancer and other related cancers.
Researchers at the University of Missouri have developed a new cancer detection and treatment method using nanoparticles that target specific receptors on tumor cells. The gold nanoparticles can be targeted to prostate, breast, or lung cancer cells, providing valuable imaging and therapeutic tools for early cancer detection and therapy.
Researchers from Georgetown University Medical Center are studying multiple ways to address treatment-resistant breast cancers. A third approach involves triggering vulnerable cells to respond to existing treatments, while another study focuses on targeting orphan nuclear receptors to prevent resistance.
Researchers found that high levels of transforming growth factor beta 1 (TGF-β1) in breast cells may indicate atypical hyperplasia, a potentially precancerous condition. The study suggests that TGF-β1 could be part of a panel of genes and proteins used to identify women at risk of developing breast cancer.
Researchers at IRB Barcelona discover that microRNAs regulate Myc protein levels through the molecule Mei-P26, providing new insights into cancer development. The study found that miRNAs affect Myc expression in Drosophila, suggesting a finely tuned mechanism to maintain optimal levels of both.
Researchers at Lund University and the University of Gothenburg have discovered a breast milk component, HAMLET, that selectively kills cancer cells without harming healthy ones. Laboratory experiments have shown HAMLET to be effective against various types of cancer.
Researchers found that MiRNA-21 interferes with trastuzumab (Herceptin) therapy by blocking the PTEN gene, leading to tumor suppressor loss and increased resistance to the drug. Overexpression of miRNA-21 was correlated with poor patient response to Herceptin and disease progression in HER2-positive breast cancer patients.
Researchers at Stanford University School of Medicine have identified a new genetic marker, called HOTAIR, that is significantly more prevalent in aggressive breast cancer cases. High levels of HOTAIR expression are associated with increased risk of metastasis and poorer survival rates for women with breast cancer.
Researchers discovered breast stem cells are exquisitely sensitive to oestrogen and progesterone, a finding that explains decades of evidence linking breast cancer risk to exposure to female hormones. The discovery also revealed the RANK ligand pathway is responsible for indirect control of breast stem cells in pregnancy.
A University of British Columbia graduate student has discovered a mechanism to silence retroviruses, which could lead to new cancer treatments. The protein ESET is crucial in preventing endogenous retrovirus activity in mouse embryonic stem cells and may hold promise for cancer therapies.
Researchers discover how breast cancer cells become resistant to hormone-dependent treatments like tamoxifen by activating a specific biochemical cascade. The study reveals the permanent stimulation of cyclic AMP in cells refractory to therapy, providing key answers to understanding resistance.
Canadian researchers have identified a previously hidden channel in humans that allows anti-cancer agents like Bleomycin to target leukemia cells. This discovery may revolutionize treatment for acute myeloid leukemia, a cancer affecting white blood cells.
Researchers at Lombardi Comprehensive Cancer Center are working on a five-year $7.5 million grant to understand the role of the estrogen receptor in breast cells, aiming to develop more advanced and targeted therapies for ER+ breast cancer cases. The project involves collaborative research with Virginia Tech and Fox Chase Cancer Center.
Women with rare ATM gene mutations and radiation exposure may be at higher risk for a second breast cancer in the opposite breast. Researchers found a statistically significant increase in contralateral breast cancer among women with deleterious missense variants and radiation exposure.
Researchers emphasize the need for improved technologies to detect circulating tumor cells (CTC's) due to their metastasizing ability. The current standardized test, CellSearch, has limitations and can only count CTC's, making it essential to explore additional technologies.
A study published in Oncogene reveals that microtentacles, extensions of plasma membrane on breast cancer cells, play a key role in metastasis. Targeting these microtentacles may provide a new way to prevent or slow the growth of secondary cancers.
A new clinical trial, PINC Trial, is testing the effectiveness of chloroquine in treating pre-invasive breast cancer. The trial aims to prevent breast cancer cells from becoming deadly by killing pre-invasive cancer cells using a novel therapy with chloroquine.
New research published in the FASEB Journal suggests that DHA and its derivatives can effectively kill neuroblastoma and other cancer cells. The study found that toxic byproducts of DHA were even more effective at killing cancer cells, providing a promising new avenue for anti-cancer treatment.
Monash University scientists have identified a new way to treat castrate-resistant prostate cancer cells using estrogen receptors. The study shows that activating these receptors can cause cell death in patients with advanced prostate cancer.
Researchers found that bitter melon extract significantly decreased proliferation and induced death in breast cancer cells. The study suggests that this extract may become a chemopreventive agent against breast cancer, but additional studies are needed to confirm its efficacy.
A research team led by Dr. Velusamy Rangasamy and Dr. Ajay Rana has identified a key protein that can serve as a target for estrogen-receptor positive breast cancer treatment. This finding could lead to the development of more targeted therapies to improve chemotherapy effectiveness.
Researchers at Saint Louis University have found that bitter melon extract significantly induces death in breast cancer cells and decreases their growth and spread. The study, published in Cancer Research, suggests that bitter melon extract may be a promising area of research for breast cancer treatment.